Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Equillium (Nasdaq: EQ) reported third-quarter financial results and began human testing of EQ504, with proof-of-mechanism data expected in Q2 2027. Third-quarter net loss widened to $4.583 million from $4.230 million a year earlier, while loss per share narrowed to $0.04 from $0.06. R&D expenses rose to $2.488 million; administrative expenses fell to $2.560 million.
Cash and equivalents totaled $53.322 million at September 30, 2026. An October 26 equity financing raised approximately $20 million gross, bringing supplemental pro forma cash to approximately $72.0 million, excluding subsequent cash use. Equillium expects funding to support planned operations into 2029. The Phase 1 trial involves approximately 70 healthy participants. Subject to supportive results, the company plans an ulcerative colitis proof-of-concept study in the second half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointOctober 26 equity financing delivered approximately $20 million in gross proceeds. 18% of market cap
- Moderate pointEQ504 Phase 1 trial initiated in October 2026, with first participant dosing completed.
- Moderate pointCash and equivalents increased to $53.322 million at September 30, 2026, versus $30.277 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Equillium expects available funding to support currently planned operations into 2029.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Equillium plans an ulcerative colitis proof-of-concept study in the second half of 2027, subject to supportive results.
- Moderate pointNine-month net loss narrowed to $14.587 million, or $0.14 per share, from $18.623 million, or $0.41.
7 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.EQ504 topline results, including proof-of-mechanism assessments, are expected in Q2 2027.
- Minor pointNonclinical EQ504 data demonstrated effects on barrier integrity, inflammatory chemokine production and immune regulation.
- Minor pointThird-quarter G&A expenses fell to $2.560 million from $3.274 million in 2025.
- Minor pointThird-quarter other income, net, increased to $465,000 from $345,000 in 2025.
- Minor pointNine-month R&D expenses fell to $8.228 million from $11.307 million in 2025.
- Minor pointNine-month G&A expenses fell to $7.585 million from $8.365 million in 2025.
- Minor pointNine-month other income, net, increased to $1.226 million from $1.049 million in 2025.
Negative
- Moderate pointThird-quarter net loss widened to $4.583 million from $4.230 million; per-share loss narrowed to $0.04 from $0.06.
- Moderate pointNine-month weighted-average common shares increased to 106,726,715 from 45,651,900 in 2025.
- Minor pointThird-quarter R&D expenses rose to $2.488 million from $1.301 million in 2025.
- Minor pointThird-quarter weighted-average common shares increased to 111,923,380 from 65,322,753 in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned ulcerative colitis study initiation remains subject to supportive Phase 1 results.
Key Figures
- Phase 1 participants
- approximately 70 healthy participants
- EQ504 first-in-human study
- Proof-of-mechanism data
- Q2 2027
- Topline data expected from the Phase 1 trial
- Ulcerative colitis study
- second half of 2027
- Planned proof-of-concept study, subject to supportive results
- October financing
- approximately $20 million gross proceeds
- Second tranche closed October 26, 2026
- Cash and cash equivalents
- $53.3 million
- As of September 30, 2026
- Pro forma cash
- approximately $72.0 million
- After estimated net proceeds from October funding
- Cash runway
- into 2029
- Expected to fund currently planned operations
- Net loss
- $4.6 million, compared with $4.2 million
- Third quarter 2026 versus third quarter 2025
Previous Earnings Reports
-
Reported EQ504 Phase 1 plans, $57.2 million in cash, and runway into 2029.
-
Outlined EQ504 Phase 1 plans and reported private-placement funding and runway into 2029.
-
Planned an EQ504 Phase 1 study and disclosed private-placement funding with Q3 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetics medical
pharmacodynamics medical
cyp1a1 medical
aryl hydrocarbon receptor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027
Cash equivalents of
Cash runway expected into 2029
LA JOLLA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting recent progress with EQ504, its novel small-molecule aryl hydrocarbon receptor (AhR) modulator.
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,” said Bruce Steel, Chief Executive Officer of Equillium. “We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease. We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027. Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
Recent Corporate and Clinical Highlights:
Initiated Phase 1 clinical trial of EQ504
In October 2026, Equillium initiated a first-in-human, randomized, double-blind, placebo-controlled study in Australia evaluating single and multiple ascending doses of EQ504 in approximately 70 healthy participants. The trial is designed to characterize safety, tolerability, pharmacokinetics and pharmacodynamics, and establish proof of mechanism of EQ504. The multiple ascending dose portion will include longitudinal gastrointestinal mucosal biopsies, including measurement of CYP1A1 expression, to assess AhR target engagement and localized biological activity in the gastrointestinal tract. Equillium expects to report topline data, including proof-of-mechanism assessments, in the second quarter of 2027. Subject to supportive results, Equillium plans to initiate a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.
Milestone Closing of
On October 26, 2026, concurrent with the first patient dosed in the Phase 1 clinical trial, Equillium closed the second tranche of the Company's previously announced August 2025 equity private placement agreement, resulting in aggregate gross proceeds of approximately
Presented new nonclinical data further characterizing EQ504’s effects on epithelial barrier repair and immune regulation
Data presented at the 7th International AHR Conference demonstrated EQ504’s activity across complementary epithelial and immune pathways relevant to intestinal inflammation, including effects on barrier integrity, inflammatory chemokine production and immune regulation. Additional data presented at the 50th Anniversary La Jolla Immunology Conference further characterized coordinated AhR signaling across epithelial and immune compartments, supporting the potential of EQ504 to restore intestinal homeostasis through a differentiated, non-immunosuppressive mechanism of action.
Third Quarter 2026 Financial Results:
Cash and cash equivalents totaled
Research and development (R&D) expenses for the third quarter of 2026 were
General and administrative (G&A) expenses for the third quarter of 2026 were
Net loss for the third quarter of 2026 was
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal immunoregulatory mechanism of action without broad immune suppression, designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. Equillium is also evaluating the potential of EQ504 for additional indications, including inflammatory lung diseases through inhaled formulations.
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat serious autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential”, “will”, “designed to” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for reporting data from the Phase 1 study of EQ504; the potential benefits of EQ504, including its potential ability to address key epithelial and immune pathways involved in inflammatory disease; the anticipated initiation of a placebo-controlled proof-of-concept study, or the expected timeline for initiating such study, in patients with ulcerative colitis; the expected use of proceeds from the Milestone Closing; and Equillium’s expectations that its financial position and cash runway is sufficient to fund its currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and nonclinical studies; risks associated with relying on pro forma financial information; whether the results from clinical and nonclinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
| Equillium, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (In thousands) | |||||||
| (unaudited) | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 53,322 | $ | 30,277 | |||
| Prepaid expenses and other assets | 1,818 | 952 | |||||
| Operating lease right-of-use assets | 671 | 658 | |||||
| Total assets | $ | 55,811 | $ | 31,887 | |||
| Current liabilities | |||||||
| Accounts payable and other current liabilities | $ | 2,819 | $ | 2,934 | |||
| Total current liabilities | 2,819 | 2,934 | |||||
| Long-term operating lease liabilities | 313 | 356 | |||||
| Total liabilities | 3,132 | 3,290 | |||||
| Total stockholders' equity | 52,679 | 28,597 | |||||
| Total liabilities and stockholders' equity | $ | 55,811 | $ | 31,887 | |||
| Equillium, Inc. | |||||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | $ | 2,488 | $ | 1,301 | $ | 8,228 | $ | 11,307 | |||||||||
| General and administrative | 2,560 | 3,274 | 7,585 | 8,365 | |||||||||||||
| Total operating expenses | 5,048 | 4,575 | 15,813 | 19,672 | |||||||||||||
| Loss from operations | (5,048 | ) | (4,575 | ) | (15,813 | ) | (19,672 | ) | |||||||||
| Total other income, net | 465 | 345 | 1,226 | 1,049 | |||||||||||||
| Net loss | $ | (4,583 | ) | $ | (4,230 | ) | $ | (14,587 | ) | $ | (18,623 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.14 | ) | $ | (0.41 | ) | |||||
| Weighted-average number of common shares outstanding, basic and diluted | 111,923,380 | 65,322,753 | 106,726,715 | 45,651,900 | |||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Equillium report EQ504 Phase 1 results?
Equillium expects EQ504 Phase 1 topline data, including proof-of-mechanism assessments, in the second quarter of 2027. The trial began in October 2026 and evaluates approximately 70 healthy participants.
How much did Equillium raise in its October 2026 financing?
Equillium closed financing generating approximately $20 million in gross proceeds on October 26, 2026. This was the second tranche of its August 2025 equity private placement agreement, triggered by first participant dosing in the EQ504 Phase 1 trial.
How is Equillium testing whether EQ504 engages its biological target?
The multiple ascending dose portion of the Phase 1 trial includes repeated gastrointestinal tissue biopsies measuring CYP1A1 expression to assess engagement of the aryl hydrocarbon receptor target and localized biological activity. The randomized, double-blind, placebo-controlled study in Australia also evaluates safety, tolerability, drug exposure and biological effects.